MARK yields 133333.33% · ABBV yields 3.06%● Live data
📍 MARK pulled ahead of the other in Year 1
Combined, MARK + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MARK + ABBV for your $10,000?
Remark Holdings, Inc. primarily focuses on the development and deployment of artificial intelligence-based solutions for businesses and software developers. It operates a data and AI software platform under the Remark AI name in the United States and the KanKan AI name in the Asia Pacific region that offers AI-based computer vision products, computing devices, and software-as-a-service solutions for the retail, urban life cycle, workplace and food safety, railway safety, and biosafety industries. The company also provides Thermal kits, which includes a thermal imaging camera, calibrating device, computer to monitor the video feed, supporting equipment, and AI software to scan crowds and areas of high foot traffic for indications that certain persons with elevated temperatures may require secondary screening; and rPad thermal imaging devices, a single-post stand to scan individuals on a one-by-one basis for authorized entry. In addition, it owns and operates Sharecare, a web-based platform that facilitates search for health and wellness information; and Bikini.com, an e-commerce website that sells swimwear and accessories in the latest styles, as well as offers advertising services. The company was formerly known as Remark Media, Inc. and changed its name to Remark Holdings, Inc. in April 2017. Remark Holdings, Inc. was incorporated in 2006 and is headquartered in Las Vegas, Nevada.
Full MARK Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.